Skip to main content

Table 4 Comparative costs (US$) for first-line treatment of MCRC with XELOX and FOLFOX4 from a societal perspective

From: Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement

   XELOX
(n = 30)
Mean (SD)
FOLFOX4
(n = 30)
Mean (SD)
Scheduled costs per cycle
Treatment cost 2,046 (325) 2,152 (307)
Patient time cost 51 (-)* 265(-)*
Patient travel cost 42 (-)* 33 (-)*
Total scheduled cost per cycle 2,139 2,450
Total scheduled cost per patient 15,544 22,539
Other unscheduled costs
Treatment cost 240 (364) 421 (890)
Patient time cost 59 (-)* 99 (-)*
Patient travel cost 17 (-)* 14 (-)*
Total unscheduled cost per cycle 315 534
Total unscheduled cost per patient 2,292 4,915
Total cost per patient 17,836 27,455
  1. * These are estimated rather than measured (see methods) therefore no SD is calculated.